S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)

相似書籍

• P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
  由: Silva-Pinto, A. C., et al.
  出版: (2022)
• O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
  由: A., SILVA-PINTO, et al.
  出版: (2022)
• P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
  由: Karki, Nabin Raj, et al.
  出版: (2021)
• The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
  由: Delgado, Julio, et al.
  出版: (2021)
• Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
  由: Riley, Tanya R, et al.
  出版: (2019)